Sovateltide
Also known as: AET-100, Endotel, ET-100, IRL-1620, PMZ-1620, Sovateltide
Source Sovateltide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Sovateltide (IRL‑1620) is a synthetic peptide ET_B receptor agonist approved in India for the treatment of acute ischemic stroke. It is administered intravenously shortly after stroke onset to improve neurological outcomes.
Mechanism of Action
Activates ET_B receptors on endothelial and neuronal cells, promoting vasodilation, angiogenesis, neurogenesis and anti‑apoptotic pathways, thereby providing neuroprotection in acute ischemic stroke.
Routes of Administration
Goals & Uses
- Reduction of infarct volumeNeuroprotectionLow
- Neurological recovery after acute ischemic strokeNeuroprotection / NeurorestorationModerate
- Acute ischemic stroke treatmentNeurologyModerate
- Promotion of neurogenesisNeuroregenerationModerate
- Cerebral angiogenesisVascular RemodelingLow
Contraindications
- Known hypersensitivity to sovateltide or excipientsAllergy/ImmunologyHigh
- Severe hepatic impairmentOrganModerateLiver function concerns
- Known hypersensitivity to sovateltide or any excipientsAllergyModerate
- Hemorrhagic strokeNeurologicalHigh
Adverse Effects
- Injection site reactionsLocalUncommon
- HeadacheNeurologicCommonPain in the head or upper neck
- HypotensionCardiovascularUncommonLow blood pressure
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- Transient hypotensionCardiovascularUncommon
Drug Interactions
- Tissue plasminogen activator (tPA / alteplase)Low
- Concurrent vasodilatorsModerate
- Antihypertensive agentsModerate
- Endothelin receptor antagonists (e.g., bosentan, ambrisentan)High
Population Constraints
- Patients with active malignancyOncologyRelative
- Severe renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeAbsolute
- Pregnant womenReproductiveRelative
Regulatory Status
- European UnionUnapprovedNo marketing authorization in the European Union.
- United StatesUnapprovedInvestigational; not approved by FDA.
- United KingdomUnapprovedNot licensed by MHRA.
Has received regulatory approval in India (CDSCO) for acute ischemic stroke as an adjunct to standard of care. Designated as an investigational new drug (IND) in the US context. Developed by Pharmazz Inc. Phase III trial results reported from India.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Sovateltide?
Sovateltide (IRL‑1620) is a synthetic peptide ET_B receptor agonist approved in India for the treatment of acute ischemic stroke. It is administered intravenously shortly after stroke onset to improve neurological outcomes.
What is Sovateltide used for?
Sovateltide is educationally associated with: Reduction of infarct volume, Neurological recovery after acute ischemic stroke, Acute ischemic stroke treatment, Promotion of neurogenesis, Cerebral angiogenesis. Educational only — not medical advice.
How is Sovateltide administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Sovateltide?
Reported adverse effects include: Injection site reactions, Headache, Hypotension, Nausea, Transient hypotension. This list is not exhaustive — consult a qualified clinician.
Who should avoid Sovateltide?
Recorded contraindications: Known hypersensitivity to sovateltide or excipients, Severe hepatic impairment, Known hypersensitivity to sovateltide or any excipients, Hemorrhagic stroke. Consult a qualified clinician before use.